A Leading Pharmaceutical Brand Increased Adherence 29% YoY with Swoop’s Patented Predictive Non-Adherence Audiences
With an increased incidence in substance use disorders (SUDs), a MAT therapy wanted to increase adherence within its patient population to drive positive patient outcomes. Leveraging Swoop’s patented predictive technology, the brand was able to accurately identify patients most likely to become non-adherent and activate them programmatically across premium inventory.
Help patients start and stay on therapy programs prescribed by their doctors
NimbleRx, a Swoop Company, connects prescription fulfillment capabilities with commercial intelligence to turn real-world signals into action, improve medication adherence, and reduce treatment delays.
Honored by innovation awards from the BIG and PM360, Swoop’s predictive audiences showcase how pharmaceutical marketing can help improve patient’s health outcomes.